AUSTIN, Texas, March 12, 2015 /PRNewswire/ -- XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, Xilonix Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human monoclonal antibody (Xilonix) for the treatment of metastatic colon cancer.
The website, www.XCITECOLONTRIAL.com provides the locations for all open sites, a pre-screening questionnaire to help individuals determine if they are eligible for the trial, and a call center to answer questions about the trial and site locations.
Total enrollment is expected to consist of 600 patients. The primary objective of the XCITE trial is to assess the ability of Xilonix to improve overall survival in patients with metastatic colorectal cancer who have failed standard therapies. Xilonix contains an anti-inflammatory antibody, which is being tested for its ability to inhibit tumor growth and metastasis by interrupting crucial signals that are necessary for the spread of cancer. In addition, Xilonix may help to improve fatigue, muscle loss and anxiety caused from tumor related inflammation.
ABOUT XBIOTECH
XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
Contact:
Ashley Otero
XBiotech
aotero@xbiotech.com
512.386.2930
Logo - http://photos.prnewswire.com/prnh/20150312/181290LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xbiotech-launches-website-and-call-center-to-inform-cancer-patients-about-new-xilonix-therapy-and-phase-iii-clinical-study-300049738.html
SOURCE XBiotech
Help employers find you! Check out all the jobs and post your resume.
